ID   ASSY_HUMAN              Reviewed;         412 AA.
AC   P00966; Q6LDL2; Q86UZ0; Q96GT4;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2002, sequence version 2.
DT   10-MAY-2017, entry version 196.
DE   RecName: Full=Argininosuccinate synthase {ECO:0000305};
DE            EC=6.3.4.5 {ECO:0000269|PubMed:18473344, ECO:0000269|PubMed:27287393, ECO:0000269|PubMed:8792870};
DE   AltName: Full=Citrulline--aspartate ligase;
GN   Name=ASS1 {ECO:0000312|HGNC:HGNC:758};
GN   Synonyms=ASS {ECO:0000312|HGNC:HGNC:758};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6194510; DOI=10.1093/nar/11.18.6505;
RA   Bock H.-G.O., Su T.-S., O'Brien W.E., Beaudet A.L.;
RT   "Sequence for human argininosuccinate synthetase cDNA.";
RL   Nucleic Acids Res. 11:6505-6512(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6321498;
RA   Freytag S.O., Bock H.-G.O., Beaudet A.L., O'Brien W.E.;
RT   "Molecular structures of human argininosuccinate synthetase
RT   pseudogenes. Evolutionary and mechanistic implications.";
RL   J. Biol. Chem. 259:3160-3166(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CTLN1 LEU-108;
RP   ARG-179; VAL-362 AND ARG-390.
RX   PubMed=11941481; DOI=10.1007/s00439-002-0686-6;
RA   Haeberle J., Pauli S., Linnebank M., Kleijer W.J., Bakker H.D.,
RA   Wanders R.J.A., Harms E., Koch H.G.;
RT   "Structure of the human argininosuccinate synthetase gene and an
RT   improved system for molecular diagnostics in patients with classical
RT   and mild citrullinemia.";
RL   Hum. Genet. 110:327-333(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Small intestine;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24.
RX   PubMed=3027451; DOI=10.1007/BF01819307;
RA   Jinno Y., Nomiyama H., Matuo S., Shimada K., Matsuda I., Saheki T.;
RT   "Structure of the 5' end region of the human argininosuccinate
RT   synthetase gene.";
RL   J. Inherit. Metab. Dis. 8:157-159(1985).
RN   [7]
RP   PROTEIN SEQUENCE OF 148-161.
RX   PubMed=2788888;
RA   Isashiki Y., Noda T., Kobayashi K., Sase M., Saheki T., Titani K.;
RT   "Identification of essential arginine residue(s) for Mg-ATP binding of
RT   human argininosuccinate synthetase.";
RL   Protein Seq. Data Anal. 2:283-287(1989).
RN   [8]
RP   PROTEIN SEQUENCE OF 200-209.
RC   TISSUE=Colon carcinoma;
RX   PubMed=9150948; DOI=10.1002/elps.1150180344;
RA   Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
RT   "A two-dimensional gel database of human colon carcinoma proteins.";
RL   Electrophoresis 18:605-613(1997).
RN   [9]
RP   TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=1708740; DOI=10.1016/0378-1119(91)90125-U;
RA   Surh L.C., Beaudet A.L., O'Brien W.E.;
RT   "Molecular characterization of the murine argininosuccinate synthetase
RT   locus.";
RL   Gene 99:181-189(1991).
RN   [10]
RP   CHARACTERIZATION OF VARIANTS CLNT1 VAL-192; ARG-280; CYS-272 AND
RP   TRP-304, FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=8792870;
RA   Shaheen N., Kobayashi K., Terazono H., Fukushige T., Horiuchi M.,
RA   Saheki T.;
RT   "Characterization of human wild-type and mutant argininosuccinate
RT   synthetase proteins expressed in bacterial cells.";
RL   Enzyme Protein 48:251-264(1994).
RN   [11]
RP   INTERACTION WITH NMRAL1.
RX   PubMed=17496144; DOI=10.1073/pnas.0700480104;
RA   Zheng X., Dai X., Zhao Y., Chen Q., Lu F., Yao D., Yu Q., Liu X.,
RA   Zhang C., Gu X., Luo M.;
RT   "Restructuring of the dinucleotide-binding fold in an NADP(H) sensor
RT   protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:8809-8814(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-180 AND THR-219, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-219, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-113 AND THR-219, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH CITRULLINE AND
RP   ASPARTATE, AND SUBUNIT.
RX   PubMed=18323623; DOI=10.1107/S0907444907067455;
RA   Karlberg T., Collins R., van den Berg S., Flores A., Hammarstrom M.,
RA   Hogbom M., Holmberg Schiavone L., Uppenberg J.;
RT   "Structure of human argininosuccinate synthetase.";
RL   Acta Crystallogr. D 64:279-286(2008).
RN   [17]
RP   INVOLVEMENT IN CTLN1, AND VARIANTS CTLN1 SER-14; HIS-157; ASN-180;
RP   TRP-304; SER-324; TRP-363 AND ARG-390.
RX   PubMed=2358466;
RA   Kobayashi K., Jackson M.J., Tick D.B., O'Brien W.E., Beaudet A.L.;
RT   "Heterogeneity of mutations in argininosuccinate synthetase causing
RT   human citrullinemia.";
RL   J. Biol. Chem. 265:11361-11367(1990).
RN   [18]
RP   VARIANTS CTLN1 LEU-18 AND CYS-86.
RX   PubMed=1943692;
RA   Kobayashi K., Rosenbloom C., Beaudet A.L., O'Brien W.E.;
RT   "Additional mutations in argininosuccinate synthetase causing
RT   citrullinemia.";
RL   Mol. Biol. Med. 8:95-100(1991).
RN   [19]
RP   VARIANTS CTLN1 THR-118; VAL-192; CYS-272; ARG-280; TRP-304 AND
RP   LEU-363.
RX   PubMed=7977368;
RA   Kobayashi K., Shaheen N., Terazono H., Saheki T.;
RT   "Mutations in argininosuccinate synthetase mRNA of Japanese patients,
RT   causing classical citrullinemia.";
RL   Am. J. Hum. Genet. 55:1103-1112(1994).
RN   [20]
RP   VARIANTS CTLN1 ALA-69; LEU-108; ASP-117; ILE-119; GLN-270 AND ARG-390.
RX   PubMed=11708871; DOI=10.1006/mgme.2001.3221;
RA   Vilaseca M.A., Kobayashi K., Briones P., Lambruschini N.,
RA   Campistol J., Tabata A., Alomar A., Rodes M., Lluch M., Saheki T.;
RT   "Phenotype and genotype heterogeneity in Mediterranean
RT   citrullinemia.";
RL   Mol. Genet. Metab. 74:396-398(2001).
RN   [21]
RP   VARIANTS CTLN1 ARG-19; HIS-86; SER-95; SER-96; ASP-117; SER-117;
RP   CYS-157; ARG-179; LYS-191; HIS-265; MET-269; CYS-272; LYS-283;
RP   TRP-304; GLN-310; SER-324; VAL-362; GLN-363; TRP-363; ILE-389 AND
RP   ARG-390.
RX   PubMed=12815590; DOI=10.1002/humu.10230;
RA   Gao H.-Z., Kobayashi K., Tabata A., Tsuge H., Iijima M., Yasuda T.,
RA   Kalkanoglu H.S., Dursun A., Tokatli A., Coskun T., Trefz F.K.,
RA   Skladal D., Mandel H., Seidel J., Kodama S., Shirane S., Ichida T.,
RA   Makino S., Yoshino M., Kang J.-H., Mizuguchi M., Barshop B.A.,
RA   Fuchinoue S., Seneca S., Zeesman S., Knerr I., Rodes M., Wasant P.,
RA   Yoshida I., De Meirleir L., Abdul-Jalil M., Begum L., Horiuchi M.,
RA   Katunuma N., Nakagawa S., Saheki T.;
RT   "Identification of 16 novel mutations in the argininosuccinate
RT   synthetase gene and genotype-phenotype correlation in 38 classical
RT   citrullinemia patients.";
RL   Hum. Mutat. 22:24-34(2003).
RN   [22]
RP   VARIANTS CTLN1 SER-14; LEU-40; GLN-127; ARG-179; ASP-190; GLU-202;
RP   MET-263; MET-269; SER-324; GLY-345 AND VAL-362.
RX   PubMed=14680976; DOI=10.1016/j.ymgme.2003.08.002;
RA   Haeberle J., Pauli S., Schmidt E., Schulze-Eilfing B., Berning C.,
RA   Koch H.G.;
RT   "Mild citrullinemia in Caucasians is an allelic variant of
RT   argininosuccinate synthetase deficiency (citrullinemia type 1).";
RL   Mol. Genet. Metab. 80:302-306(2003).
RN   [23]
RP   VARIANT CTLN1 ARG-310.
RX   PubMed=15863597; DOI=10.1097/01.AOG.0000157769.90230.24;
RA   Enns G.M., O'Brien W.E., Kobayashi K., Shinzawa H., Pellegrino J.E.;
RT   "Postpartum 'psychosis' in mild argininosuccinate synthetase
RT   deficiency.";
RL   Obstet. Gynecol. 105:1244-1246(2005).
RN   [24]
RP   VARIANTS CTLN1 ASN-124; HIS-157; GLN-270; GLN-279; LYS-283; SER-324;
RP   GLY-363 AND ARG-390.
RX   PubMed=16475226; DOI=10.1002/pd.1390;
RA   Kleijer W.J., Garritsen V.H., van der Sterre M.L., Berning C.,
RA   Haeberle J., Huijmans J.G.M.;
RT   "Prenatal diagnosis of citrullinemia and argininosuccinic aciduria:
RT   evidence for a transmission ratio distortion in citrullinemia.";
RL   Prenat. Diagn. 26:242-247(2006).
RN   [25]
RP   VARIANTS CTLN1 CYS-265 AND VAL-302, CHARACTERIZATION OF VARIANTS CTLN1
RP   THR-118; ARG-179; VAL-263; CYS-265; VAL-302; SER-324; VAL-362 AND
RP   ARG-390, FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=18473344; DOI=10.1002/humu.20784;
RA   Berning C., Bieger I., Pauli S., Vermeulen T., Vogl T., Rummel T.,
RA   Hoehne W., Koch H.G., Rolinski B., Gempel K., Haeberle J.;
RT   "Investigation of citrullinemia type I variants by in vitro expression
RT   studies.";
RL   Hum. Mutat. 29:1222-1227(2008).
RN   [26]
RP   VARIANTS CTLN1 PRO-79; HIS-96; GLN-127; TRP-127; PRO-160; GLN-191;
RP   PRO-206; CYS-265; THR-277; ILE-284; SER-291; GLY-296; VAL-324;
RP   PHE-341; ARG-347 AND ASP-359.
RX   PubMed=19006241; DOI=10.1002/humu.20847;
RA   Engel K., Hoehne W., Haeberle J.;
RT   "Mutations and polymorphisms in the human argininosuccinate synthetase
RT   (ASS1) gene.";
RL   Hum. Mutat. 30:300-307(2009).
RN   [27]
RP   VARIANTS CTLN1 LYS-283 AND ARG-337.
RX   PubMed=23611581; DOI=10.1016/j.braindev.2013.03.005;
RA   Wu T.F., Liu Y.P., Li X.Y., Wang Q., Song J.Q., Yang Y.L.;
RT   "Prenatal diagnosis of citrullinemia type 1: a Chinese family with a
RT   novel mutation of the ASS1 gene.";
RL   Brain Dev. 36:264-267(2014).
RN   [28]
RP   VARIANTS CTLN1 PRO-91; CYS-157; ILE-180; LYS-283 AND ARG-390, AND
RP   VARIANT LEU-127.
RX   PubMed=24889030; DOI=10.1016/j.ymgme.2014.05.004;
RA   Miller M.J., Soler-Alfonso C.R., Grund J.E., Fang P., Sun Q.,
RA   Elsea S.H., Sutton V.R.;
RT   "Improved standards for prenatal diagnosis of citrullinemia.";
RL   Mol. Genet. Metab. 112:205-209(2014).
RN   [29]
RP   VARIANTS CTLN1 GLY-141 AND CYS-265.
RX   PubMed=25179242; DOI=10.1016/j.cca.2014.08.028;
RA   Kimani J.K., Wei T., Chol K., Li Y., Yu P., Ye S., Huang X., Qi M.;
RT   "Functional analysis of novel splicing and missense mutations
RT   identified in the ASS1 gene in classical citrullinemia patients.";
RL   Clin. Chim. Acta 438:323-329(2015).
RN   [30]
RP   VARIANTS CTLN1 PRO-91; LEU-96; SER-117; THR-118; ILE-119; ASN-124;
RP   CYS-157; HIS-157; CYS-272; HIS-272 AND LEU-272, CHARACTERIZATION OF
RP   VARIANTS CTLN1 PRO-91; SER-95; HIS-96; LEU-96; SER-96; SER-117;
RP   THR-118; ILE-119; ASN-124; GLN-127; TRP-127; CYS-157; HIS-157;
RP   ASN-180; ILE-180; GLN-191; GLN-270; CYS-272; HIS-272 AND LEU-272,
RP   CHARACTERIZATION OF VARIANT LEU-127, CATALYTIC ACTIVITY, PATHWAY,
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=27287393; DOI=10.1136/jmedgenet-2016-103937;
RA   Diez-Fernandez C., Wellauer O., Gemperle C., Ruefenacht V.,
RA   Fingerhut R., Haeberle J.;
RT   "Kinetic mutations in argininosuccinate synthetase deficiency:
RT   characterisation and in vitro correction by substrate
RT   supplementation.";
RL   J. Med. Genet. 53:710-719(2016).
RN   [31]
RP   VARIANTS CTLN1 27-GLN--LYS-412 DEL; ILE-64; PRO-79; 97-CYS--LYS-412
RP   DEL; CYS-100; HIS-100; ASP-111; CYS-117; 138-GLN--LYS-412 DEL;
RP   SER-157; PRO-160; 163-TYR--LYS-412 DEL; PRO-164; LYS-184; ASP-190;
RP   PRO-206; ARG-230; ILE-237; PRO-258; VAL-258; CYS-265; 275-GLY--LYS-412
RP   DEL; THR-277; 279-ARG--LYS-412 DEL; ILE-284; PRO-290; SER-291;
RP   GLY-296; ASP-299; VAL-302; GLY-306; CYS-307; 311-GLN--LYS-412 DEL;
RP   MET-321; SER-324; VAL-324; HIS-335; PHE-341; 344-ARG--LYS-412 DEL;
RP   ARG-347; VAL-356; 357-GLN--LYS-412 DEL; ASP-359; 380-GLN--LYS-412 DEL
RP   AND PRO-389.
RX   PubMed=28111830; DOI=10.1002/humu.23184;
RA   Diez-Fernandez C., Ruefenacht V., Haeberle J.;
RT   "Mutations in the human argininosuccinate synthetase (ASS1) gene,
RT   impact on patients, common changes, and structural considerations.";
RL   Hum. Mutat. 0:0-0(2017).
CC   -!- FUNCTION: One of the enzymes of the urea cycle, the metabolic
CC       pathway transforming neurotoxic amonia produced by protein
CC       catabolism into inocuous urea in the liver of ureotelic animals.
CC       Catalyzes the formation of arginosuccinate from aspartate,
CC       citrulline and ATP and together with ASL it is responsible for the
CC       biosynthesis of arginine in most body tissues.
CC       {ECO:0000305|PubMed:18473344, ECO:0000305|PubMed:27287393,
CC       ECO:0000305|PubMed:8792870}.
CC   -!- CATALYTIC ACTIVITY: ATP + L-citrulline + L-aspartate = AMP +
CC       diphosphate + N(omega)-(L-arginino)succinate.
CC       {ECO:0000269|PubMed:18473344, ECO:0000269|PubMed:27287393,
CC       ECO:0000269|PubMed:8792870}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=112 uM for citrulline (at pH 7.0 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:18473344};
CC         KM=68 uM for aspartate (at pH 7.0 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:18473344};
CC         Vmax=143 nmol/min/mg enzyme toward citrulline (at pH 7.0 and 37
CC         degrees Celsius) {ECO:0000269|PubMed:18473344};
CC         Vmax=116 nmol/min/mg enzyme toward aspartate (at pH 7.0 and 37
CC         degrees {ECO:0000269|PubMed:18473344};
CC   -!- PATHWAY: Amino-acid biosynthesis; L-arginine biosynthesis; L-
CC       arginine from L-ornithine and carbamoyl phosphate: step 2/3.
CC       {ECO:0000305|PubMed:18473344, ECO:0000305|PubMed:27287393,
CC       ECO:0000305|PubMed:8792870}.
CC   -!- PATHWAY: Nitrogen metabolism; urea cycle; (N(omega)-L-
CC       arginino)succinate from L-aspartate and L-citrulline: step 1/1.
CC       {ECO:0000305|PubMed:18473344, ECO:0000305|PubMed:27287393,
CC       ECO:0000305|PubMed:8792870}.
CC   -!- SUBUNIT: Homotetramer (PubMed:18323623). Interacts with NMRAL1
CC       (PubMed:17496144). {ECO:0000269|PubMed:17496144,
CC       ECO:0000269|PubMed:18323623}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-536842, EBI-536842;
CC       P10398:ARAF; NbExp=4; IntAct=EBI-536842, EBI-365961;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000305|PubMed:27287393}.
CC   -!- TISSUE SPECIFICITY: Expressed in adult liver.
CC       {ECO:0000269|PubMed:1708740}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal liver and kidney.
CC       {ECO:0000269|PubMed:1708740}.
CC   -!- DISEASE: Citrullinemia 1 (CTLN1) [MIM:215700]: The classic form of
CC       citrullinemia, an autosomal recessive disease characterized
CC       primarily by elevated serum and urine citrulline levels. Ammonia
CC       intoxication is another manifestation. It is a disorder of the
CC       urea cycle, usually manifesting in the first few days of life.
CC       Affected infants appear normal at birth, but as ammonia builds up
CC       in the body they present symptoms such as lethargy, poor feeding,
CC       vomiting, seizures and loss of consciousness. Less commonly, a
CC       milder form can develop later in childhood or adulthood.
CC       {ECO:0000269|PubMed:11708871, ECO:0000269|PubMed:11941481,
CC       ECO:0000269|PubMed:12815590, ECO:0000269|PubMed:14680976,
CC       ECO:0000269|PubMed:15863597, ECO:0000269|PubMed:16475226,
CC       ECO:0000269|PubMed:18473344, ECO:0000269|PubMed:19006241,
CC       ECO:0000269|PubMed:1943692, ECO:0000269|PubMed:2358466,
CC       ECO:0000269|PubMed:23611581, ECO:0000269|PubMed:24889030,
CC       ECO:0000269|PubMed:25179242, ECO:0000269|PubMed:27287393,
CC       ECO:0000269|PubMed:28111830, ECO:0000269|PubMed:7977368}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the argininosuccinate synthase family. Type
CC       1 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Argininosuccinate synthetase 1 (ASS1);
CC       Note=Leiden Open Variation Database (LOVD);
CC       URL="http://www.lovd.nl/ASS1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X01630; CAA25771.1; -; mRNA.
DR   EMBL; L00084; AAA51783.1; -; Genomic_DNA.
DR   EMBL; L00079; AAA51783.1; JOINED; Genomic_DNA.
DR   EMBL; L00080; AAA51783.1; JOINED; Genomic_DNA.
DR   EMBL; L00081; AAA51783.1; JOINED; Genomic_DNA.
DR   EMBL; L00082; AAA51783.1; JOINED; Genomic_DNA.
DR   EMBL; L00083; AAA51783.1; JOINED; Genomic_DNA.
DR   EMBL; AY034076; AAK67487.1; -; Genomic_DNA.
DR   EMBL; AK027126; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BC009243; AAH09243.1; -; mRNA.
DR   EMBL; BC021676; AAH21676.1; -; mRNA.
DR   EMBL; M34903; AAA51782.1; -; Genomic_DNA.
DR   CCDS; CCDS6933.1; -.
DR   PIR; A01195; AJHURS.
DR   RefSeq; NP_000041.2; NM_000050.4.
DR   RefSeq; NP_446464.1; NM_054012.3.
DR   RefSeq; XP_005272257.1; XM_005272200.3.
DR   UniGene; Hs.160786; -.
DR   PDB; 2NZ2; X-ray; 2.40 A; A=1-412.
DR   PDBsum; 2NZ2; -.
DR   ProteinModelPortal; P00966; -.
DR   SMR; P00966; -.
DR   BioGrid; 106937; 86.
DR   DIP; DIP-34055N; -.
DR   IntAct; P00966; 24.
DR   MINT; MINT-5000467; -.
DR   STRING; 9606.ENSP00000253004; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB00125; L-Arginine.
DR   DrugBank; DB00128; L-Aspartic Acid.
DR   DrugBank; DB00155; L-Citrulline.
DR   iPTMnet; P00966; -.
DR   PhosphoSitePlus; P00966; -.
DR   BioMuta; ASS1; -.
DR   DMDM; 20141195; -.
DR   EPD; P00966; -.
DR   PaxDb; P00966; -.
DR   PeptideAtlas; P00966; -.
DR   PRIDE; P00966; -.
DR   DNASU; 445; -.
DR   Ensembl; ENST00000352480; ENSP00000253004; ENSG00000130707.
DR   Ensembl; ENST00000372393; ENSP00000361469; ENSG00000130707.
DR   Ensembl; ENST00000372394; ENSP00000361471; ENSG00000130707.
DR   GeneID; 445; -.
DR   KEGG; hsa:445; -.
DR   CTD; 445; -.
DR   DisGeNET; 445; -.
DR   GeneCards; ASS1; -.
DR   GeneReviews; ASS1; -.
DR   H-InvDB; HIX0025782; -.
DR   HGNC; HGNC:758; ASS1.
DR   HPA; HPA020896; -.
DR   HPA; HPA020934; -.
DR   MalaCards; ASS1; -.
DR   MIM; 215700; phenotype.
DR   MIM; 603470; gene.
DR   neXtProt; NX_P00966; -.
DR   OpenTargets; ENSG00000130707; -.
DR   Orphanet; 247546; Acute neonatal citrullinemia type I.
DR   Orphanet; 247573; Adult-onset citrullinemia type I.
DR   PharmGKB; PA162376926; -.
DR   eggNOG; KOG1706; Eukaryota.
DR   eggNOG; COG0137; LUCA.
DR   GeneTree; ENSGT00390000004524; -.
DR   HOGENOM; HOG000230093; -.
DR   HOVERGEN; HBG001717; -.
DR   InParanoid; P00966; -.
DR   KO; K01940; -.
DR   OMA; QCEVVTF; -.
DR   OrthoDB; EOG091G0AIR; -.
DR   PhylomeDB; P00966; -.
DR   TreeFam; TF300736; -.
DR   BioCyc; MetaCyc:HS05425-MONOMER; -.
DR   BRENDA; 6.3.4.5; 2681.
DR   Reactome; R-HSA-70635; Urea cycle.
DR   SABIO-RK; P00966; -.
DR   UniPathway; UPA00068; UER00113.
DR   UniPathway; UPA00158; UER00272.
DR   EvolutionaryTrace; P00966; -.
DR   GeneWiki; Argininosuccinate_synthetase_1; -.
DR   GenomeRNAi; 445; -.
DR   PRO; PR:P00966; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000130707; -.
DR   CleanEx; HS_ASS1; -.
DR   ExpressionAtlas; P00966; baseline and differential.
DR   Genevisible; P00966; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0016597; F:amino acid binding; IMP:BHF-UCL.
DR   GO; GO:0004055; F:argininosuccinate synthase activity; IMP:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0006526; P:arginine biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0000053; P:argininosuccinate metabolic process; IMP:BHF-UCL.
DR   GO; GO:0006531; P:aspartate metabolic process; IMP:BHF-UCL.
DR   GO; GO:0071499; P:cellular response to laminar fluid shear stress; IMP:BHF-UCL.
DR   GO; GO:0000052; P:citrulline metabolic process; IMP:BHF-UCL.
DR   GO; GO:1903038; P:negative regulation of leukocyte cell-cell adhesion; IMP:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0000050; P:urea cycle; IMP:UniProtKB.
DR   CDD; cd01999; Argininosuccinate_Synthase; 1.
DR   Gene3D; 3.40.50.620; -; 1.
DR   Gene3D; 3.90.1260.10; -; 1.
DR   HAMAP; MF_00005; Arg_succ_synth_type1; 1.
DR   InterPro; IPR001518; Arginosuc_synth.
DR   InterPro; IPR018223; Arginosuc_synth_CS.
DR   InterPro; IPR023434; Arginosuc_synth_type_1_subfam.
DR   InterPro; IPR024074; AS_cat/multimer_dom_body.
DR   InterPro; IPR014729; Rossmann-like_a/b/a_fold.
DR   PANTHER; PTHR11587; PTHR11587; 1.
DR   Pfam; PF00764; Arginosuc_synth; 1.
DR   TIGRFAMs; TIGR00032; argG; 1.
DR   PROSITE; PS00564; ARGININOSUCCIN_SYN_1; 1.
DR   PROSITE; PS00565; ARGININOSUCCIN_SYN_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Amino-acid biosynthesis; Arginine biosynthesis;
KW   ATP-binding; Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Ligase; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Urea cycle.
FT   CHAIN         1    412       Argininosuccinate synthase.
FT                                /FTId=PRO_0000148554.
FT   NP_BIND      10     18       ATP. {ECO:0000250}.
FT   NP_BIND     115    123       ATP. {ECO:0000250}.
FT   BINDING      36     36       ATP; via amide nitrogen and carbonyl
FT                                oxygen. {ECO:0000250}.
FT   BINDING      87     87       Citrulline.
FT                                {ECO:0000269|PubMed:18323623}.
FT   BINDING      92     92       Citrulline.
FT                                {ECO:0000269|PubMed:18323623}.
FT   BINDING     119    119       Aspartate. {ECO:0000269|PubMed:18323623}.
FT   BINDING     123    123       Aspartate. {ECO:0000269|PubMed:18323623}.
FT   BINDING     123    123       Citrulline.
FT                                {ECO:0000269|PubMed:18323623}.
FT   BINDING     124    124       Aspartate. {ECO:0000269|PubMed:18323623}.
FT   BINDING     127    127       Citrulline.
FT                                {ECO:0000269|PubMed:18323623}.
FT   BINDING     180    180       Citrulline.
FT                                {ECO:0000269|PubMed:18323623}.
FT   BINDING     189    189       Citrulline.
FT                                {ECO:0000269|PubMed:18323623}.
FT   BINDING     270    270       Citrulline.
FT                                {ECO:0000269|PubMed:18323623}.
FT   BINDING     282    282       Citrulline.
FT                                {ECO:0000269|PubMed:18323623}.
FT   MOD_RES      87     87       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P09034}.
FT   MOD_RES     113    113       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     180    180       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     219    219       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VARIANT      14     14       G -> S (in CTLN1; dbSNP:rs121908636).
FT                                {ECO:0000269|PubMed:14680976,
FT                                ECO:0000269|PubMed:2358466}.
FT                                /FTId=VAR_000681.
FT   VARIANT      18     18       S -> L (in CTLN1; dbSNP:rs121908643).
FT                                {ECO:0000269|PubMed:1943692}.
FT                                /FTId=VAR_000682.
FT   VARIANT      19     19       C -> R (in CTLN1).
FT                                {ECO:0000269|PubMed:12815590}.
FT                                /FTId=VAR_015891.
FT   VARIANT      27    412       Missing (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078387.
FT   VARIANT      40     40       Q -> L (in CTLN1).
FT                                {ECO:0000269|PubMed:14680976}.
FT                                /FTId=VAR_058337.
FT   VARIANT      64     64       V -> I (in CTLN1; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078388.
FT   VARIANT      69     69       V -> A (in CTLN1; dbSNP:rs771594651).
FT                                {ECO:0000269|PubMed:11708871}.
FT                                /FTId=VAR_016013.
FT   VARIANT      79     79       S -> P (in CTLN1).
FT                                {ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058338.
FT   VARIANT      86     86       R -> C (in CTLN1; dbSNP:rs121908644).
FT                                {ECO:0000269|PubMed:1943692}.
FT                                /FTId=VAR_000683.
FT   VARIANT      86     86       R -> H (in CTLN1; dbSNP:rs575001023).
FT                                {ECO:0000269|PubMed:12815590}.
FT                                /FTId=VAR_015892.
FT   VARIANT      91     91       T -> P (in CTLN1; decreased affinity for
FT                                aspartate; decreased affinity for
FT                                citrulline; decreased argininosuccinate
FT                                synthase activity).
FT                                {ECO:0000269|PubMed:24889030,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_078389.
FT   VARIANT      95     95       R -> S (in CTLN1; increased thermal
FT                                stability; loss of argininosuccinate
FT                                synthase activity).
FT                                {ECO:0000269|PubMed:12815590,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_015893.
FT   VARIANT      96     96       P -> H (in CTLN1; decreased affinity for
FT                                aspartate; decreased affinity for
FT                                citrulline; decreased argininosuccinate
FT                                synthase activity).
FT                                {ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_058339.
FT   VARIANT      96     96       P -> L (in CTLN1; decreased thermal
FT                                stability; decreased affinity for
FT                                aspartate; decreased affinity for
FT                                citrulline; loss of argininosuccinate
FT                                synthase activity).
FT                                {ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_078390.
FT   VARIANT      96     96       P -> S (in CTLN1; no effect on thermal
FT                                stability; decreased argininosuccinate
FT                                synthase activity).
FT                                {ECO:0000269|PubMed:12815590,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_015894.
FT   VARIANT      97    412       Missing (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078391.
FT   VARIANT     100    100       R -> C (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078392.
FT   VARIANT     100    100       R -> H (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078393.
FT   VARIANT     108    108       R -> L (in CTLN1; dbSNP:rs35269064).
FT                                {ECO:0000269|PubMed:11708871,
FT                                ECO:0000269|PubMed:11941481}.
FT                                /FTId=VAR_016014.
FT   VARIANT     111    111       A -> D (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078394.
FT   VARIANT     117    117       G -> C (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078395.
FT   VARIANT     117    117       G -> D (in CTLN1).
FT                                {ECO:0000269|PubMed:11708871,
FT                                ECO:0000269|PubMed:12815590}.
FT                                /FTId=VAR_015896.
FT   VARIANT     117    117       G -> S (in CTLN1; decreased thermal
FT                                stability; loss of argininosuccinate
FT                                synthase activity; dbSNP:rs770944877).
FT                                {ECO:0000269|PubMed:12815590,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_015895.
FT   VARIANT     118    118       A -> T (in CTLN1; decreased thermal
FT                                stability; decreased affinity for
FT                                aspartate; decreased affinity for
FT                                citrulline; decreased argininosuccinate
FT                                synthase activity; dbSNP:rs775305020).
FT                                {ECO:0000269|PubMed:18473344,
FT                                ECO:0000269|PubMed:27287393,
FT                                ECO:0000269|PubMed:7977368}.
FT                                /FTId=VAR_000684.
FT   VARIANT     119    119       T -> I (in CTLN1; decreased thermal
FT                                stability; loss of argininosuccinate
FT                                synthase activity).
FT                                {ECO:0000269|PubMed:11708871,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_016015.
FT   VARIANT     124    124       D -> N (in CTLN1; loss of
FT                                argininosuccinate synthase activity).
FT                                {ECO:0000269|PubMed:16475226,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_058340.
FT   VARIANT     127    127       R -> L (increased thermal stability; loss
FT                                of argininosuccinate synthase activity).
FT                                {ECO:0000269|PubMed:24889030,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_078396.
FT   VARIANT     127    127       R -> Q (in CTLN1; increased thermal
FT                                stability; loss of argininosuccinate
FT                                synthase activity; dbSNP:rs201623252).
FT                                {ECO:0000269|PubMed:14680976,
FT                                ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_058341.
FT   VARIANT     127    127       R -> W (in CTLN1; severe clinical course;
FT                                loss of argininosuccinate synthase
FT                                activity; dbSNP:rs771794639).
FT                                {ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_058342.
FT   VARIANT     138    412       Missing (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078397.
FT   VARIANT     141    141       V -> G (in CTLN1).
FT                                {ECO:0000269|PubMed:25179242}.
FT                                /FTId=VAR_072792.
FT   VARIANT     157    157       R -> C (in CTLN1; decreased thermal
FT                                stability; loss of argininosuccinate
FT                                synthase activity; dbSNP:rs770585183).
FT                                {ECO:0000269|PubMed:12815590,
FT                                ECO:0000269|PubMed:24889030,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_015897.
FT   VARIANT     157    157       R -> H (in CTLN1; loss of
FT                                argininosuccinate synthase activity;
FT                                dbSNP:rs121908637).
FT                                {ECO:0000269|PubMed:16475226,
FT                                ECO:0000269|PubMed:2358466,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_000685.
FT   VARIANT     157    157       R -> S (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078398.
FT   VARIANT     160    160       L -> P (in CTLN1).
FT                                {ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058343.
FT   VARIANT     163    412       Missing (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078399.
FT   VARIANT     164    164       A -> P (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078400.
FT   VARIANT     179    179       W -> R (in CTLN1; mild; decreased
FT                                affinity for aspartate; decreased
FT                                affinity for citrulline; decreased
FT                                argininosuccinate synthase activity;
FT                                dbSNP:rs121908646).
FT                                {ECO:0000269|PubMed:11941481,
FT                                ECO:0000269|PubMed:12815590,
FT                                ECO:0000269|PubMed:14680976,
FT                                ECO:0000269|PubMed:18473344}.
FT                                /FTId=VAR_015898.
FT   VARIANT     180    180       S -> I (in CTLN1; increased thermal
FT                                stability; loss of argininosuccinate
FT                                synthase activity).
FT                                {ECO:0000269|PubMed:24889030,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_078401.
FT   VARIANT     180    180       S -> N (in CTLN1; decreased thermal
FT                                stability; decreased affinity for
FT                                aspartate; decreased affinity for
FT                                citrulline; decreased argininosuccinate
FT                                synthase activity; dbSNP:rs121908638).
FT                                {ECO:0000269|PubMed:2358466,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_000686.
FT   VARIANT     184    184       N -> K (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078402.
FT   VARIANT     190    190       Y -> D (in CTLN1).
FT                                {ECO:0000269|PubMed:14680976,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058344.
FT   VARIANT     191    191       E -> K (in CTLN1; dbSNP:rs777828000).
FT                                {ECO:0000269|PubMed:12815590}.
FT                                /FTId=VAR_015899.
FT   VARIANT     191    191       E -> Q (in CTLN1; loss of
FT                                argininosuccinate synthase activity).
FT                                {ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_058345.
FT   VARIANT     192    192       A -> V (in CTLN1; decreased protein
FT                                abundance). {ECO:0000269|PubMed:7977368,
FT                                ECO:0000269|PubMed:8792870}.
FT                                /FTId=VAR_000687.
FT   VARIANT     202    202       A -> E (in CTLN1; dbSNP:rs376371866).
FT                                {ECO:0000269|PubMed:14680976}.
FT                                /FTId=VAR_058346.
FT   VARIANT     206    206       L -> P (in CTLN1).
FT                                {ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058347.
FT   VARIANT     230    230       G -> R (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078403.
FT   VARIANT     237    237       N -> I (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078404.
FT   VARIANT     258    258       A -> P (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078405.
FT   VARIANT     258    258       A -> V (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078406.
FT   VARIANT     263    263       V -> M (in CTLN1; mild clinical course;
FT                                no effect on affinity for aspartate; no
FT                                effect on affinity for citrulline;
FT                                decreased argininosuccinate synthase
FT                                activity; dbSNP:rs192838388).
FT                                {ECO:0000269|PubMed:14680976,
FT                                ECO:0000269|PubMed:18473344}.
FT                                /FTId=VAR_058348.
FT   VARIANT     265    265       R -> C (in CTLN1; severe clinical course;
FT                                loss of argininosuccinate synthase
FT                                activity; dbSNP:rs148918985).
FT                                {ECO:0000269|PubMed:18473344,
FT                                ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:25179242,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058349.
FT   VARIANT     265    265       R -> H (in CTLN1; dbSNP:rs398123131).
FT                                {ECO:0000269|PubMed:12815590}.
FT                                /FTId=VAR_015900.
FT   VARIANT     269    269       V -> M (in CTLN1; dbSNP:rs370595480).
FT                                {ECO:0000269|PubMed:12815590,
FT                                ECO:0000269|PubMed:14680976}.
FT                                /FTId=VAR_015901.
FT   VARIANT     270    270       E -> Q (in CTLN1; loss of
FT                                argininosuccinate synthase activity;
FT                                dbSNP:rs775163147).
FT                                {ECO:0000269|PubMed:11708871,
FT                                ECO:0000269|PubMed:16475226,
FT                                ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_016007.
FT   VARIANT     272    272       R -> C (in CTLN1; increased thermal
FT                                stability; decreased affinity for
FT                                aspartate; decreased affinity for
FT                                citrulline; decreased argininosuccinate
FT                                synthase activity; dbSNP:rs762387914).
FT                                {ECO:0000269|PubMed:12815590,
FT                                ECO:0000269|PubMed:27287393,
FT                                ECO:0000269|PubMed:7977368,
FT                                ECO:0000269|PubMed:8792870}.
FT                                /FTId=VAR_000688.
FT   VARIANT     272    272       R -> H (in CTLN1; increased thermal
FT                                stability; decreased affinity for
FT                                aspartate; decreased affinity for
FT                                citrulline; decreased argininosuccinate
FT                                synthase activity).
FT                                {ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_078407.
FT   VARIANT     272    272       R -> L (in CTLN1; increased thermal
FT                                stability; decreased affinity for
FT                                aspartate; decreased affinity for
FT                                citrulline; decreased argininosuccinate
FT                                synthase activity).
FT                                {ECO:0000269|PubMed:27287393}.
FT                                /FTId=VAR_078408.
FT   VARIANT     275    412       Missing (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078409.
FT   VARIANT     277    277       K -> T (in CTLN1).
FT                                {ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058350.
FT   VARIANT     279    412       Missing (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078410.
FT   VARIANT     279    279       R -> Q (in CTLN1; dbSNP:rs371265106).
FT                                {ECO:0000269|PubMed:16475226}.
FT                                /FTId=VAR_016008.
FT   VARIANT     280    280       G -> R (in CTLN1; loss of
FT                                argininosuccinate synthase activity).
FT                                {ECO:0000269|PubMed:7977368,
FT                                ECO:0000269|PubMed:8792870}.
FT                                /FTId=VAR_000689.
FT   VARIANT     283    283       E -> K (in CTLN1; dbSNP:rs765338121).
FT                                {ECO:0000269|PubMed:12815590,
FT                                ECO:0000269|PubMed:16475226,
FT                                ECO:0000269|PubMed:23611581,
FT                                ECO:0000269|PubMed:24889030}.
FT                                /FTId=VAR_015902.
FT   VARIANT     284    284       T -> I (in CTLN1; mild clinical course).
FT                                {ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058351.
FT   VARIANT     290    290       L -> P (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078411.
FT   VARIANT     291    291       Y -> S (in CTLN1).
FT                                {ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058352.
FT   VARIANT     296    296       D -> G (in CTLN1).
FT                                {ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058353.
FT   VARIANT     299    299       A -> D (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078412.
FT   VARIANT     302    302       M -> V (in CTLN1; no effect on affinity
FT                                for aspartate; no effect on affinity for
FT                                citrulline; decreased argininosuccinate
FT                                synthase activity).
FT                                {ECO:0000269|PubMed:18473344,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058354.
FT   VARIANT     304    304       R -> W (in CTLN1; decreased protein
FT                                abundance; dbSNP:rs121908642).
FT                                {ECO:0000269|PubMed:12815590,
FT                                ECO:0000269|PubMed:2358466,
FT                                ECO:0000269|PubMed:7977368}.
FT                                /FTId=VAR_000690.
FT   VARIANT     306    306       V -> G (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078413.
FT   VARIANT     307    307       R -> C (in CTLN1; dbSNP:rs183276875).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058355.
FT   VARIANT     310    310       K -> Q (in CTLN1; dbSNP:rs121908648).
FT                                {ECO:0000269|PubMed:12815590}.
FT                                /FTId=VAR_016009.
FT   VARIANT     310    310       K -> R (in CTLN1; dbSNP:rs199751308).
FT                                {ECO:0000269|PubMed:15863597}.
FT                                /FTId=VAR_015903.
FT   VARIANT     311    412       Missing (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078414.
FT   VARIANT     321    321       V -> M (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078415.
FT   VARIANT     324    324       G -> S (in CTLN1; loss of
FT                                argininosuccinate synthase activity;
FT                                dbSNP:rs121908639).
FT                                {ECO:0000269|PubMed:12815590,
FT                                ECO:0000269|PubMed:14680976,
FT                                ECO:0000269|PubMed:16475226,
FT                                ECO:0000269|PubMed:18473344,
FT                                ECO:0000269|PubMed:2358466,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_000691.
FT   VARIANT     324    324       G -> V (in CTLN1).
FT                                {ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058356.
FT   VARIANT     335    335       R -> H (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078416.
FT   VARIANT     337    337       C -> R (in CTLN1).
FT                                {ECO:0000269|PubMed:23611581}.
FT                                /FTId=VAR_078417.
FT   VARIANT     341    341       S -> F (in CTLN1).
FT                                {ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058357.
FT   VARIANT     344    412       Missing (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078418.
FT   VARIANT     345    345       V -> G (in CTLN1).
FT                                {ECO:0000269|PubMed:14680976}.
FT                                /FTId=VAR_058358.
FT   VARIANT     347    347       G -> R (in CTLN1; severe clinical
FT                                course). {ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058359.
FT   VARIANT     356    356       G -> V (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078419.
FT   VARIANT     357    412       Missing (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078420.
FT   VARIANT     359    359       Y -> D (in CTLN1; mild clinical course).
FT                                {ECO:0000269|PubMed:19006241,
FT                                ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_058360.
FT   VARIANT     362    362       G -> V (in CTLN1; mild; no effect on
FT                                affinity for aspartate; no effect on
FT                                affinity for citrulline; decreased
FT                                argininosuccinate synthase activity;
FT                                dbSNP:rs121908647).
FT                                {ECO:0000269|PubMed:11941481,
FT                                ECO:0000269|PubMed:12815590,
FT                                ECO:0000269|PubMed:14680976,
FT                                ECO:0000269|PubMed:18473344}.
FT                                /FTId=VAR_015904.
FT   VARIANT     363    363       R -> G (in CTLN1).
FT                                {ECO:0000269|PubMed:16475226}.
FT                                /FTId=VAR_016010.
FT   VARIANT     363    363       R -> L (in CTLN1).
FT                                {ECO:0000269|PubMed:7977368}.
FT                                /FTId=VAR_000692.
FT   VARIANT     363    363       R -> Q (in CTLN1; dbSNP:rs771937610).
FT                                {ECO:0000269|PubMed:12815590}.
FT                                /FTId=VAR_016011.
FT   VARIANT     363    363       R -> W (in CTLN1; dbSNP:rs121908640).
FT                                {ECO:0000269|PubMed:12815590,
FT                                ECO:0000269|PubMed:2358466}.
FT                                /FTId=VAR_000693.
FT   VARIANT     380    412       Missing (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078421.
FT   VARIANT     389    389       T -> I (in CTLN1).
FT                                {ECO:0000269|PubMed:12815590}.
FT                                /FTId=VAR_016012.
FT   VARIANT     389    389       T -> P (in CTLN1).
FT                                {ECO:0000269|PubMed:28111830}.
FT                                /FTId=VAR_078422.
FT   VARIANT     390    390       G -> R (in CTLN1; loss of
FT                                argininosuccinate synthase activity;
FT                                dbSNP:rs121908641).
FT                                {ECO:0000269|PubMed:11708871,
FT                                ECO:0000269|PubMed:11941481,
FT                                ECO:0000269|PubMed:12815590,
FT                                ECO:0000269|PubMed:16475226,
FT                                ECO:0000269|PubMed:18473344,
FT                                ECO:0000269|PubMed:2358466,
FT                                ECO:0000269|PubMed:24889030}.
FT                                /FTId=VAR_000694.
FT   CONFLICT    325    327       FWH -> LRP (in Ref. 1; CAA25771 and 2;
FT                                AAA51783). {ECO:0000305}.
FT   STRAND        5     10       {ECO:0000244|PDB:2NZ2}.
FT   HELIX        15     26       {ECO:0000244|PDB:2NZ2}.
FT   STRAND       29     39       {ECO:0000244|PDB:2NZ2}.
FT   HELIX        44     54       {ECO:0000244|PDB:2NZ2}.
FT   STRAND       57     63       {ECO:0000244|PDB:2NZ2}.
FT   HELIX        65     71       {ECO:0000244|PDB:2NZ2}.
FT   HELIX        73     78       {ECO:0000244|PDB:2NZ2}.
FT   TURN         84     86       {ECO:0000244|PDB:2NZ2}.
FT   TURN         90     93       {ECO:0000244|PDB:2NZ2}.
FT   HELIX        94    109       {ECO:0000244|PDB:2NZ2}.
FT   STRAND      112    115       {ECO:0000244|PDB:2NZ2}.
FT   HELIX       124    135       {ECO:0000244|PDB:2NZ2}.
FT   STRAND      140    142       {ECO:0000244|PDB:2NZ2}.
FT   HELIX       144    146       {ECO:0000244|PDB:2NZ2}.
FT   HELIX       148    151       {ECO:0000244|PDB:2NZ2}.
FT   HELIX       158    166       {ECO:0000244|PDB:2NZ2}.
FT   STRAND      181    183       {ECO:0000244|PDB:2NZ2}.
FT   STRAND      188    190       {ECO:0000244|PDB:2NZ2}.
FT   HELIX       193    196       {ECO:0000244|PDB:2NZ2}.
FT   HELIX       204    206       {ECO:0000244|PDB:2NZ2}.
FT   TURN        213    215       {ECO:0000244|PDB:2NZ2}.
FT   STRAND      221    228       {ECO:0000244|PDB:2NZ2}.
FT   STRAND      231    237       {ECO:0000244|PDB:2NZ2}.
FT   TURN        238    240       {ECO:0000244|PDB:2NZ2}.
FT   HELIX       247    261       {ECO:0000244|PDB:2NZ2}.
FT   STRAND      265    271       {ECO:0000244|PDB:2NZ2}.
FT   STRAND      277    283       {ECO:0000244|PDB:2NZ2}.
FT   HELIX       285    301       {ECO:0000244|PDB:2NZ2}.
FT   HELIX       304    323       {ECO:0000244|PDB:2NZ2}.
FT   STRAND      326    328       {ECO:0000244|PDB:2NZ2}.
FT   HELIX       329    341       {ECO:0000244|PDB:2NZ2}.
FT   TURN        342    344       {ECO:0000244|PDB:2NZ2}.
FT   STRAND      347    354       {ECO:0000244|PDB:2NZ2}.
FT   STRAND      357    364       {ECO:0000244|PDB:2NZ2}.
FT   HELIX       372    375       {ECO:0000244|PDB:2NZ2}.
FT   HELIX       385    404       {ECO:0000244|PDB:2NZ2}.
SQ   SEQUENCE   412 AA;  46530 MW;  47CAD2373AE47E47 CRC64;
     MSSKGSVVLA YSGGLDTSCI LVWLKEQGYD VIAYLANIGQ KEDFEEARKK ALKLGAKKVF
     IEDVSREFVE EFIWPAIQSS ALYEDRYLLG TSLARPCIAR KQVEIAQREG AKYVSHGATG
     KGNDQVRFEL SCYSLAPQIK VIAPWRMPEF YNRFKGRNDL MEYAKQHGIP IPVTPKNPWS
     MDENLMHISY EAGILENPKN QAPPGLYTKT QDPAKAPNTP DILEIEFKKG VPVKVTNVKD
     GTTHQTSLEL FMYLNEVAGK HGVGRIDIVE NRFIGMKSRG IYETPAGTIL YHAHLDIEAF
     TMDREVRKIK QGLGLKFAEL VYTGFWHSPE CEFVRHCIAK SQERVEGKVQ VSVLKGQVYI
     LGRESPLSLY NEELVSMNVQ GDYEPTDATG FININSLRLK EYHRLQSKVT AK
//
